Endometrial cancer (EC) is a major cause of mortality for patients worldwide. Although its incidence differs throughout the world, it is estimated to be the most common cancer of the female genital tract and the fourth most common cancer in North America and Europe ([@bib20]; [@bib10]).

Early-stage EC restricted to the uterus represents nearly 80% of all cases ([@bib11], [@bib12]; [@bib10]). The estimated 5-year overall survival for these patients is 95% but decreases substantially to 67.0% and 15.9% for local and distant disease, respectively ([@bib13]; [@bib35]; [@bib9]; [@bib3]). Moreover, the recurrence rate for early-stage EC is widely variable ranging from 2 to 26% ([@bib13]; [@bib9]; [@bib3]; [@bib30]; [@bib40]; [@bib31]). In this specific setting, many epidemiological and histological factors such as increasing age, depth of myometrial invasion, histological tumour type and grade, presence of lymphovascular space invasion (LVSI) and the International Federation of Gynecology and Obstetrics (FIGO) classification ([@bib32]) have been reported to be correlated with a higher risk of recurrence and nodal metastases ([@bib11]; [@bib27]; [@bib22]; [@bib30]; [@bib40]; [@bib31]; [@bib10]).

Over the last decade, these criteria have been aggregated into several risk stratification systems (RSS) that are currently used worldwide to guide decision-making and clinical trial design ([@bib13]; [@bib22]; [@bib40]; [@bib10]; [@bib7]). The assumption is based on defining recurrence risk groups, which can help identify clinical situations where multimodality therapy and/or nodal staging should be proposed for high-risk patients or, conversely, single modality or wait-and-see strategies for low-risk patients. Although the core variables of these RSS are very similar ([@bib13]; [@bib22]; [@bib40]; [@bib10]; [@bib7]), finally, it appears that for major RSS: (i) most have never been externally validated; (ii) accuracy is not reported and (iii) no simultaneous comparisons using the same cohort have been performed.

Hence, the aim of this study was to compare five major RSS ([@bib13]; [@bib22]; [@bib40]; [@bib10]; [@bib7]) in a multicenter cohort of patients with early-stage EC with regard to their discriminative performance in stratifying the risk of recurrence and nodal metastases.

Materials and Methods
=====================

Study population
----------------

The data of 553 patients with apparent early-stage EC, who received primary surgical treatment between January 2001 and December 2012, were abstracted from five institutions with maintained EC databases in France (Tenon University Hospital, Reims University Hospital, Dijon Cancer Center, Creteil hospital and Jeanne de Flandre University Hospital) and from the Senti-Endo trial ([@bib6]). All patients had undergone a preoperative endometrial biopsy. All enrolled patients underwent a preoperative MRI unless contraindicated, in which case a CT scan was performed. Patients with histologically proven EC were staged on the basis of final pathological findings according to the 2009 FIGO classification ([@bib32]). Clinical and pathologic variables included patient age, surgical procedure, 2009 FIGO stage and final pathological analysis (histological type and grade, depth of myometrial invasion and LVSI status). A tumour was considered LVSI-positive when tumour emboli were found within a space clearly lined by endothelial cells ([@bib41]). The research protocol was approved by the institutional review board of the French college of obstetricians and gynecologists (CEROG 2014-GYN-020).

Treatment and follow-up
-----------------------

We included all women who underwent primary surgical treatment including at least total hysterectomy with bilateral salpingo-oophorectomy, with or without nodal staging (pelvic ± paraaortic lymphadenectomy) according to the current guidelines ([@bib33]; [@bib10]) and to the surgeon\'s discretion. Sentinel lymph node biopsies (SLNB) were performed by a dual intracervical injection based on the histological validation of SLN by Delpech *et al* ([@bib16]). A para-aortic lymphadenectomy was recommended for women with metastatic pelvic SLN on intraoperative histology or after final histology. Systematic pelvic and para-aortic lymphadenectomy was also recommended for patients with type 2 EC (clear-cell, serous EC and carcinosarcoma) and type 1, grade 3 with a depth of myometrial invasion \>50%. Adjuvant therapy was administered on an individual basis at the discretion of a multidisciplinary committee according to international guidelines ([@bib10]) and involved vaginal brachytherapy and/or external beam radiotherapy (EBRT) and/or chemotherapy. Clinical follow-up consisted of physical examinations and the use of imaging techniques depending on the findings. Follow-up sessions were conducted every 3 months during the first 2 years, every 6 months during the following 3 years and once a year thereafter.

RSS description
---------------

Five major RSS related to the risk stratification of early-stage EC were identified in the medical literature using PubMed: the Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC)-1 classification ([@bib13]), the Gynecologic Oncology Group (GOG) 99 classification ([@bib22]), the Survival effect of para-aortic lymphadenectomy (SEPAL) in EC classification ([@bib40]), the ESMO ([@bib10]) and ESMO-modified ([@bib7]) classifications. RSS were selected with respect to their acceptance in the literature and clinical applicability. [Table 1](#tbl1){ref-type="table"} describes the criteria for each RSS.

Recurrence events and recurrence-free survival (RFS)
----------------------------------------------------

The clinical end point was recurrence. Disease recurrence was diagnosed by biopsy or imaging studies and defined as a relapse without differentiating between their local or distant nature. RFS was defined as the time from surgery to the date of recurrence. Estimates were produced using the Kaplan--Meier method.

Statistical analysis
--------------------

### Stratification accuracy

The receiver operating characteristic area under the curve (ROC-AUC) as well as the concordance index (C-index) indicate the discriminatory properties and quantify the stratification accuracy (i.e., whether the relative ranking of individual stratification was in the correct order) ([@bib17]; [@bib18]; [@bib19]). The AUC requires binary outcomes (presence or absence of the event) and is reserved for binary logistic regression models. The c-index represents an adaptation of the AUC for censored data and is necessary when time-to-event data are used. In the current analysis, the accuracy of each RSS for RFS (censored data) was conducted using the Cox Proportional Hazards Model. Similarly to quantify the discriminatory properties of each RSS with regard to the risk for LNM, a binary logistic regression model was performed. The AUC, as well as the c-index of 0.5, represents no discriminating ability, and a value of 1.0 represents perfect discrimination.

### RSS diagnostic accuracy

Sensitivity, specificity, negative predictive values, positive predictive values and the overall diagnostic accuracy (ODA) (i.e., the probability of a patient being correctly classified by the RSS) with 95% CI were calculated to study the diagnostic ability of each RSS to classify patients at low risk and those at high risk of recurrence and nodal metastases.

Others analysis
---------------

Statistical analysis was based on Student\'s *t*-test and the Mann--Whitney test for parametric and nonparametric continuous variables, respectively, and the *χ*^2^-test or Fisher\'s exact test, as appropriate, for categorical variables. Values of *P*\<0.05 were considered to denote significant differences. Data were managed with an Excel database (Microsoft, Redmond, WA, USA) and analysed using R 2.15 software, available online.

Results
=======

Characteristics of the study population
---------------------------------------

During the study period 553 patients with EC were documented as having received primary surgical treatment according to the following distribution: Dijon Cancer Center (*n*=122; 22%), Creteil Hospital (*n*=83; 15%), Reims University Hospital (*n*=87; 16%), Tenon University Hospital (*n*=70; 13%), Jeanne de Flandre University Hospital (*n*=97; 17%) and Senti-Endo trial (*n*=94; 17%). The demographics and clinicopathological characteristics of the whole cohort are reported in [Table 2](#tbl2){ref-type="table"}. The median age of the patients was 65.0 years (range: 31--98 years).

RFS according to each RSS
-------------------------

The median follow-up was 32 (range: 2--165) months and the median time to initial recurrence was 29 (range: 1--165) months. Overall 3-year RFS and 3-year recurrence rates were 83.9% (95% CI, 80.6--87.4) and 16.4%, respectively. Loco-regional, nodal and distant recurrences were observed in 20% (18/91), 24% (22/91) and 56% (51/91) of cases, respectively. The respective 3-year RFS according to each RSS are reported in [Figure 1](#fig1){ref-type="fig"}.

Discrimination and diagnostic accuracy of each RSS system for recurrence
------------------------------------------------------------------------

The discrimination of each RSS is reported in [Figure 2A](#fig2){ref-type="fig"}. The RSS with the highest discrimination was the ESMO-modified classification (C-index=0.73 (95% CI, 0.70--0.76)). The diagnostic accuracy of each RSS is reported in [Table 3](#tbl3){ref-type="table"}. The RSS with the highest ODA to select patients at low risk of recurrence was the PORTEC-1 classification with 56% of patients correctly stratified. The RSS with the highest ODA to select patients at increased risk of recurrence was the ESMO-modified classification with 78% of patients correctly assigned.

Discrimination and diagnostic accuracy of each RSS systems for nodal metastases
-------------------------------------------------------------------------------

Overall, 86.6% (479/553) of the patients underwent systematic nodal staging and 16.5% (79/479) of these had nodal metastases ([Table 2](#tbl2){ref-type="table"}). Discrimination of each RSS is reported in [Figure 2B](#fig2){ref-type="fig"}. The RSS with the highest discrimination was the ESMO-modified classification (AUC=0.80 (95% CI, 0.78--0.82)). The diagnostic accuracy of each RSS is reported in [Table 3](#tbl3){ref-type="table"}. The RSS with the highest ODA to select patients at low risk of nodal metastases was the PORTEC-1 classification with 56% of patients correctly stratified. The RSS with the highest ODA to select patients at increased risk of metastases was the ESMO-modified system with 77% of patients correctly assigned.

Discussion
==========

To our knowledge, this is the first study to provide a comparison of five major RSS applied to a multicenter population with early-stage EC. The results suggest that these five RSS have a poor-to-moderate discrimination for recurrence and nodal metastases. In addition, the clinical diagnostic accuracy to distinguish subgroups of patients at low- and high-risk of recurrence or nodal metastases appears to be limited and heterogeneous.

Management of women with early-stage EC remains controversial and practice patterns vary widely among gynecologic oncologists ([@bib13]; [@bib22]; [@bib3]; [@bib30]; [@bib10]; [@bib23]). This is mainly because there are several criteria defining risk groups for recurrence, unstandardised protocols for surgical staging and different indications for adjuvant therapies ([@bib13]; [@bib22]; [@bib3]; [@bib30]; [@bib10]; [@bib23]). To overcome these limitations and guide clinicians in their decision-making and in providing patient information, several authors have developed RSS to create a common nomenclature ([@bib13]; [@bib22]; [@bib12]; [@bib33]; [@bib10]; [@bib7]). Although all of these RSS include similar variables, the combination of variables differs substantially between the United States and European countries leading to widely differing practice patterns for adjuvant therapies and indications for nodal staging ([@bib13]; [@bib22]; [@bib3]; [@bib30]; [@bib10]; [@bib23]). The potential of ROC curves in medical diagnostic testing was recognised as early as 1960 ([@bib25]) as the most relevant statistical tool to describe diagnostic performance ([@bib17]; [@bib15]). Classically, the predictive accuracy of a classification is based on the assumption that all patients within a given risk group are equal. However, in practice, heterogeneity in both biological parameters and patients\' characteristics within each risk subgroup has been reported, especially for women with early-stage EC ([@bib13]; [@bib22]; [@bib6], [@bib5]; [@bib31]), leading to incorrect risk assignment. Our results confirm that the ESMO-modified classification ([@bib7]) was the RSS with the highest discrimination according to recurrence with a C-index of 0.72. We also found that the PORTEC-1 classification ([@bib13]) was the most accurate in selecting patients at low risk of recurrence with an ODA of 55% and the ESMO-modified classification ([@bib7]) more accurate in selecting patients at increased risk with an ODA of 78%. These results also suggest that these RSS are heterogeneous in terms of classification performance. Moreover, it highlights the high rate of misclassified patients whatever the RSS used and the potential risk of inadequate surgical staging and over- or under-treatment. Finally, these results underline that new biological markers or stratification tools are probably needed to improve discrimination of such classifications, resulting in a more adapted surgical staging and adjuvant treatment.

Despite a reported good overall survival, almost 15% of patients with localised disease experience recurrence during the first 2 years following initial treatment ([@bib12]; [@bib9]; [@bib3]; [@bib7]). It is therefore essential to distinguish patients at increased risk of recurrence who require systematic adjuvant EBRT and/or chemotherapy. A debate exists regarding the optimal adjuvant therapy for patients with early-stage EC. Published trials involve a wide variety of patients with different characteristics, rendering interpretation of the results somewhat difficult ([@bib13]; [@bib22]; [@bib30]; [@bib23]). Moreover, there are several differences in surgical staging from one study to another; in some trials, lymphadenectomy was systematically performed ([@bib24]; [@bib36]; [@bib39]), whereas in others it was not required ([@bib13]; [@bib26]; [@bib35]; [@bib4]; [@bib30]) or performed only in case of suspicious lymph nodes ([@bib28]; [@bib38], [@bib37]). This gives rise to an important confounding bias. Three randomised trials on adjuvant pelvic radiation versus a wait-and-see approach have shown significantly improved loco-regional control in case of additional EBRT, with no impact on overall survival ([@bib1]; [@bib13]; [@bib22]). Indeed, when focusing on the high-risk cohorts, the reported loco-regional recurrence rates vary from 13 to 23% with no adjuvant EBRT ([@bib1]; [@bib13]; [@bib22]) versus 5% when adjuvant EBRT is administered systematically ([@bib1]; [@bib13]; [@bib22]). This underlines the importance of accurate risk stratification in selecting the most adapted treatment option. Similarly, few data exist on the role of chemotherapy in early-stage EC. In high-risk EC, the Cochrane meta-analysis showed a positive impact of chemotherapy on overall survival, disease-free survival and distant metastasis ([@bib21]). However, these results may be biased by the inclusion of patients with more advanced disease once again rendering interpretation somewhat difficult ([@bib35]).

Selecting patients who might benefit from systematic nodal staging is a major issue to guide postoperative treatment in patients with early-stage EC ([@bib9]; [@bib3]; [@bib6]; [@bib31]). In this setting, a meta-analysis of two randomised trials on the impact of systematic lymphadenectomy in early-stage EC showed no benefit on overall and recurrence-free survival ([@bib9]; [@bib3]). In contrast, in the SEPAL study Todo *et al* (2010) reported a survival benefit for systematic pelvic and para-aortic lymphadenectomy especially in patients with intermediate- and high-risk EC. These results highlight that the intermediate-risk group, as currently defined by the major classifications, is a heterogeneous group of patients in terms of nodal metastases rendering indications for complete surgical staging and adjuvant therapies somewhat blurred. Moreover, in a retrospective study on the rate of nodal metastases in clinical stage 1 type 1 EC according to the PORTEC 1 ([@bib13]) and GOG-99 criteria ([@bib22]) for high-intermediate risk patients Nugent *et al* (2012) reported that patients have substantial risk of nodal involvement and recurrence, suggesting that complete nodal staging is crucial for this subgroup. Our results confirm that the ESMO-modified classification has the highest discrimination for nodal metastases. Moreover, we found that the PORTEC-1 RSS ([@bib13]) was the most accurate to select patients at low risk with an ODA of 56%, whereas the ESMO-modified RSS ([@bib7]) was the most accurate to select patients at high-risk with an ODA of 77%. These results underline the need in the future for precise quantification of the risk of nodal metastases using a complementary approach based on individualized prediction models such as nomograms ([@bib8]; [@bib2]). In this specific setting, [@bib2]) developed two nomograms in patients with surgically treated stage I--IV endometrioid EC to predict the probability of lymph node metastases. However, the definition of an optimal threshold to decide whether to perform secondary lymphadenectomy is lacking. Finally, the authors did not focus on women with early-stage disease, which is the subgroup with the most discrepancies in terms of nodal metastases.

Some limitations of the present study deserve to be mentioned. First, it included patients treated for early-stage EC over a relatively long period. During the data collection period, modifications in staging modalities (FIGO classification ([@bib32])) and surgical techniques (LN staging) were introduced. For example, SLNB was introduced and shown to be a possible first-line treatment for patients with early-stage EC. Indeed, Raimond *et al* (2014) recently demonstrated that SLN mapping and ultrastaging improved staging and made it possible to adapt adjuvant therapy to the risk of recurrence. Second, our cohort included patients from several centers and discrepancies in patient management might have affected our results in part. However, all included centers were regional referral centers applying the current French guidelines. Third, although the ESMO-modified classification seems to be associated to higher stratification accuracy, an external and independent validation study of the current results is needed. Fourth, although the multicentre nature of this study provides an overview of clinical practice during a long period, the overall survival analysis could not be performed. Finally, central pathology review was not available. However, dedicated pathologists from tertiary referral centers assessed all biopsies and specimens.

In conclusion, we demonstrate here that none of five major RSS shows high accuracy to stratify recurrence risk and nodal metastases in women with early-stage EC. Therefore, there is a need to revisit existing RSS using additional tools such as biological markers to better stratify patient risk in this setting. Moreover, several promising prognostic *in situ* biomarkers such as DNA ploidy, expression of P53, oestrogen and progesterone receptors have been identified ([@bib5]; [@bib29]). These biomarkers could be used in clinical practice for a more individualised management in EC. At last, the therapeutic challenge for early-stage EC lies in promoting a personalized therapeutic strategy to avoid over- or under-treatment.
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###### Description of five risk recurrence systems

  **RSS**                    **Year**   **Number of patients**  **Criteria**
  ------------------------- ---------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  PORTEC-1 ([@bib14])          2000              715             Low risk Endometrial adenocarcinoma stage Ia, grade 1  Intermediate risk Endometrial adenocarcinoma Stage I based on uterine factors Grade 1 histology and myometrial invasion of ⩾50% Grade 2 histology with any myometrial invasion Grade 3 histology with myometrial invasion \<50%  High-intermediate risk Age \>60 years with grade 1 or 2 histology and myometrial invasion \>50% Age \>60 with grade 3 histology and myometrial invasion \<50%  High-risk Stage III--IV disease Uterine serous carcinoma or clear cell carcinoma of any stage
  GOG-99 ([@bib22])            2004              382             Low risk Grade 1 or 2, endometrioid cancers confined to the endometrium stage IA  Low-intermediate risk Age ⩽50 years + ⩽2 pathologic risk factors Age 50--69 years + ⩽1 pathologic risk factor Age ⩾70 years + no pathologic risk factors (Risk factors (1) grade 2 or 3 histology; (2) positive lymphovascular space invasion; (3) myometrial invasion to outer 1/3)  High-intermediate risk (HIR) Any age + 3 pathologic risk factors Age 50--69 years + ⩾2 pathologic risk factors Age ⩾70 years + ⩾1 pathologic risk factor (Risk factors (1) grade 2 or 3 histology; (2) positive lymphovascular space invasion; (3) myometrial invasion to outer 1/3)  High-risk Stage III--IV disease, regardless of histology or grade Uterine serous carcinoma or clear cell carcinoma of any stage
  SEPAL ([@bib40])             2010              671             Low risk Stage IA IB, endometrioid type, LVSI negative  Intermediate risk Stage IA grade 3 endometrioid adenocarcinoma; any grade of non-endometrioid carcinoma (serous adenocarcinoma, clear cell adenocarcinoma or other type of carcinoma), any LVSI Stage IB, grade 1--2 endometrioid adenocarcinoma, LVSI positive Stage IB, grade 3 endometrioid adenocarcinoma; any grade of non- endometrioid carcinoma (serous adenocarcinoma, clear cell adenocarcinoma or other type of carcinoma), any LVSI Stage IC, stage II, any grade, any LVSI  High risk Stage III--IV, any grade, any LVSI
  ESMO ([@bib10])              2013              ---             Low risk Stage IA (grade 1 and grade 2) with endometrioid type  Intermediate risk Stage IA grade 3 with endometrioid type Stage IB (grade 1 and grade 2) with endometrioid type  High risk Stage IB grade 3 with endometrioid type All stages with non-endometrioid type
  ESMO modified ([@bib7])      2014              496             Low-risk ESMO/LVSI-  Low-risk ESMO/LVSI+  Intermediate-risk ESMO/LVSI-  Intermediate-risk ESMO/LVSI+  High-risk ESMO/LVSI-  High-risk ESMO/LVSI+

Abbreviations: ESMO=European Society for Medical Oncology; LVSI=lymphovascular space invasion.

###### Characteristics of the whole population

                                       **Overall population** ***n*****=553**   **No recurrence** ***n*****=462**   **Recurrence** ***n*****=91**   ***P*****-value**[a](#t2-fn2){ref-type="fn"}
  ----------------------------------- ---------------------------------------- ----------------------------------- ------------------------------- ----------------------------------------------
  Age-mean (range)                                 64.9 (31--98)                          64.4 (31--98)                     67.8 (32--88)                              0.0033
  **Histological grade**                                                                                                                           
  I                                                 48.6% (269)                            52.4% (242)                       29.7% (27)                                   
  II                                                27.5% (152)                            29.2% (135)                       18.7% (17)                                   
  III                                               23.9% (132)                            18.4% (85)                        51.6% (47)                               \<0.0001
  **Pathological type**                                                                                                                            
  1                                                 86.6% (479)                             89.2(412)                        73.6% (67)                                   
  2                                                  13.4% (74)                             10.8(50)                         26.7% (24)                                0.0001
  **Myometrial invasion**                                                                                                                          
  \<50%                                             54.3% (300)                            58.4% (270)                       32.9% (30)                                   
  ⩾50%                                              45.7% (253)                            41.6% (192)                       67.1% (61)                               \<0.0001
  **Lymphovascular space invasion**                                                                                                                
  No                                                66.4% (367)                            70.4% (325)                       46.1% (42)                                   
  Yes                                               25.3% (140)                            21.2% (98)                        46.1% (42)                                   
  NA                                                 8.3% (46)                              8.4% (39)                         7.8% (7)                                \<0.0001
  **FIGO stage**                                                                                                                                   
  I                                                 78.1% (432)                            81.8% (378)                       59.3% (54)                                   
  II                                                 7.6% (42)                              6.3% (29)                        14.3% (13)                                   
  IIIc                                               14.3% (79)                            11.9% (55)                        26.4% (24)                               \<0.0001
  Nodal staging (P/PAL)                           86.6% (479/553)                        87.1% (402/462)                    84.6% (77/91)                              0.0001
  Nodal metastasis                                 16.5% (79/479)                        13.7% (55/402)                     31.2% (24/77)                              0.0001
  **PORTEC-1 ([@bib13])**                                                                                                                          
  Low risk                                           32% (175)                              35% (163)                         13% (12)                                    
  Intermediate risk                                  19% (106)                              21% (97)                          10% ( 9)                                    
  High-intermediate risk                             24% (134)                              23% (105)                         32% ( 29)                                   
  High risk                                          25% (138)                              21% (97)                          45% ( 41)                                 ---
  **GOG-99 ([@bib22])**                                                                                                                            
  Low risk                                           51% (280)                              55% (255)                         27% (25)                                    
  Low-intermediate risk                               2% (13)                                2% (10)                           3% (3)                                     
  High-intermediate risk                             23% (129)                              23% (106)                         25% (23)                                    
  High risk                                          24% (131)                              20% (91)                          44% ( 40)                                 ---
  **SEPAL ([@bib40])**                                                                                                                             
  Low risk                                           43% (238)                              48% (221)                         19% (17)                                    
  Intermediate risk                                  43% (236)                              40% (186)                         55% (50)                                  ---
  High risk                                           14% (79)                              12% (55)                          26% (24)                                    
  **ESMO ([@bib10])**                                                                                                                              
  Low risk                                          45.1% (249)                            50.4% (233)                       17.6% (16)                                   
  Intermediate risk                                 34.5% (191)                            34.0% (157)                       37.4% (34)                                   
  High risk                                         20.4% (113)                            15.6% (72)                        45.0% (41)                                 ---
  **ESMO/LVSI ([@bib7])**                                                                                                                          
  Low-risk ESMO/LVSI−                               37.6% (208)                            41.8% (193)                       16.5% (15)                                   
  Low-risk ESMO/LVSI+                                2.7% (15)                              3.2% (15)                          0% (0)                                     
  Intermediate-risk ESMO/LVSI−                      18.8% (104)                            19.6% (90)                        15.4% (14)                                   
  Intermediate-risk ESMO/LVSI+                       13.2% (73)                            12.1% (56)                        18.7% (17)                                   
  High-risk ESMO/LVSI−                               9.9% (55)                              9.1% (42)                        14.3% (13)                                   
  High-risk ESMO/LVSI+                               9.4% (52)                              5.8% (27)                        27.4% (25)                                 ---
  NA                                                 8.4% (46)                              8.4% (39)                         7.7% (7)                                    
  **Adjuvant therapy**                                                                                                                             
  No adjuvant therapy                               18.1% (100)                            20.1% (93)                         7.7% (7)                                  ---
  EBRT ± brachytherapy                              34.7% (192)                            30.8% (142)                       54.9% (50)                                   
  Brachytherapy                                     30.1% (166)                            34.8% (161)                        5.5% (5)                                    
  Chemotherapy                                       2.3% (13)                              0.9% (4)                          9.9% (9)                                    
  Multimodal therapy                                 4.9% (27)                              3.5% (16)                        12.1% (11)                                   
  NA                                                 9.9% (55)                              9.9% (46)                         9.9% (9)                                    

Abbreviations: EBRT=External beam radiotherapy; ESMO=European Society for Medical Oncology; FIGO=Federation of Gynecology and Obstetrics; GOG=Gynecologic Oncology Group; LVSI=lymphovascular space invasion; NA=not applicable; P/PAL=pelvic and/or paraaortic lymphadenectomy; PORTEC=Post Operative Radiation Therapy in Endometrial Carcinoma; SEPAL=Survival effect of para-aortic lymphadenectomy.

Univariate logistic regression.

###### Diagnostic accuracy for recurrence

                                                                      **Low risk group (compared with other groups)**   **High risk group (compared with other groups)**                          
  ---------------------------------------------------- ------------- ------------------------------------------------- -------------------------------------------------- ------- ------- ------- -------
  PORTEC-1 ([@bib13])                                   Sensitivity                        0.132                                             0.074                         0.216   0.451   0.357   0.545
                                                        Specificity                        0.647                                             0.636                         0.664   0.790   0.772   0.809
                                                            PPV                            0.069                                             0.039                         0.112   0.297   0.236   0.360
                                                            NPV                            0.791                                             0.777                         0.811   0.880   0.859   0.900
                                                            ODA                            0.562                                             0.734                                                
  GOG-99 ([@bib22])                                     Sensitivity                        0.275                                             0.193                         0.371   0.440   0.347   0.534
                                                        Specificity                        0.448                                             0.432                         0.467   0.803   0.785   0.822
                                                            PPV                            0.089                                             0.063                         0.121   0.305   0.241   0.371
                                                            NPV                            0.758                                             0.731                         0.790   0.879   0.859   0.899
                                                            ODA                            0.420                                             0.743                                                
  SEPAL ([@bib40])                                      Sensitivity                        0.187                                             0.118                         0.278   0.264   0.187   0.350
                                                        Specificity                        0.522                                             0.508                         0.540   0.881   0.866   0.898
                                                            PPV                            0.071                                             0.045                         0.106   0.304   0.215   0.403
                                                            NPV                            0.765                                             0.745                         0.791   0.859   0.844   0.875
                                                            ODA                            0.457                                             0.769                                                
  ESMO ([@bib10])                                       Sensitivity                        0.176                                             0.109                         0.266   0.451   0.359   0.542
                                                        Specificity                        0.496                                             0.482                         0.513   0.844   0.826   0.862
                                                            PPV                            0.064                                             0.040                         0.097   0.363   0.289   0.437
                                                            NPV                            0.753                                             0.733                         0.780   0.886   0.867   0.905
                                                            ODA                            0.467                                             0.773                                                
  ESMO modified[a](#t3-fn2){ref-type="fn"} ([@bib7])    Sensitivity                        0.179                                             0.109                         0.273   0.452   0.357   0.548
                                                        Specificity                        0.508                                             0.494                         0.527   0.837   0.818   0.856
                                                            PPV                            0.067                                             0.041                         0.103   0.355   0.280   0.430
                                                            NPV                            0.757                                             0.736                         0.785   0.885   0.865   0.905
                                                            ODA                            0.453                                             0.776                                                

Abbreviations: ESMO=European Society for Medical Oncology; GOG=Gynecologic Oncology Group; NPV=negative predictive values; ODA=overall diagnostic accuracy; PORTEC=Post Operative Radiation Therapy in Endometrial Carcinoma; PPV=positive predictive values; SEPAL=Survival effect of para-aortic lymphadenectomy.

Intermediate-risk ESMO/LVSI+ and high risk groups compared with intermediate risk ESMO/LVSI- and low risk.
